MA (EU) number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Immediate Packaging	Content (concentration)	Pack size
EU/1/20/1528/018	COMIRNATY Omicron XBB.1.5	--[10]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/019	COMIRNATY Omicron XBB.1.5	--[10]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/020	COMIRNATY Omicron XBB.1.5	--[10]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	195 multidose vials (1170 doses)
EU/1/20/1528/021	COMIRNATY Omicron XBB.1.5	--[11]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	1.3 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/022	COMIRNATY Omicron XBB.1.5	--[12]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/023	COMIRNATY Omicron XBB.1.5	--[12]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/024	COMIRNATY Omicron XBB.1.5	--[13]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.4 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/025	COMIRNATY Omicron XBB.1.5	--[10]	Dispersion for injection	Intramuscular use	pre-filled syringe (cyclic-olefin copolymer)	0.432 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/026	COMIRNATY Omicron XBB.1.5	--[14]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/027	COMIRNATY Omicron XBB.1.5	--[10]	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses); fridge only
EU/1/20/1528/028	COMIRNATY JN.1	--[15]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)

EU/1/20/1528/029	COMIRNATY JN.1	--[15]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/030	COMIRNATY JN.1	--[15]	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses); fridge only
EU/1/20/1528/031	COMIRNATY JN.1	--[15]	Dispersion for injection	Intramuscular use	pre-filled syringe (cyclic-olefin copolymer)	0.432 ml (1 dose)	10 pre-filled syringes (10 doses)
EU/1/20/1528/032	COMIRNATY JN.1	--[16]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/033	COMIRNATY JN.1	--[16]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/034	COMIRNATY JN.1	--[17]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	1.3 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/035	COMIRNATY JN.1	--[18]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/036	COMIRNATY JN.1	--[19]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.4 ml (10 doses)	10 multidose vials (100 doses)
EU/1/20/1528/037	COMIRNATY KP.2	--[20]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/038	COMIRNATY KP.2	--[20]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/039	COMIRNATY KP.2	--[20]	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses); fridge only
EU/1/20/1528/040	COMIRNATY KP.2	--[21]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)

EU/1/20/1528/041	COMIRNATY KP.2	--[21]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/042	COMIRNATY KP.2	--[22]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/043	COMIRNATY JN.1	--[15]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses); fridge only
EU/1/20/1528/044	COMIRNATY KP.2	--[20]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses); fridge only
EU/1/20/1528/045	COMIRNATY LP.8.1	--[23]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/046	COMIRNATY LP.8.1	--[23]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses); fridge only
EU/1/20/1528/047	COMIRNATY LP.8.1	--[23]	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	10 pre-filled syringes (10 doses); fridge only
EU/1/20/1528/048	COMIRNATY LP.8.1	--[24]	Dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (1 dose)	10 single dose vials (10 doses)
EU/1/20/1528/049	COMIRNATY LP.8.1	--[24]	Dispersion for injection	Intramuscular use	vial (glass)	2.25 ml (6 doses)	10 multidose vials (60 doses)
EU/1/20/1528/050	COMIRNATY LP.8.1	--[25]	Concentrate for dispersion for injection	Intramuscular use	vial (glass)	0.48 ml (3 doses)	10 multidose vials (30 doses)
EU/1/20/1528/051	COMIRNATY LP.8.1	--[23]	Dispersion for injection	Intramuscular use	pre-filled syringe (glass)	0.418 ml (1 dose)	1 pre-filled syringe (1 dose); fridge only

--[10]: COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection (EU/1/20/1528/018-020, EU/1/20/1528/025, EU/1/20/1528/027):
1 dose (0.3 mL) contains 30 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--[11]: COMIRNATY Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/021):
After dilution, 1 dose (0.2 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--[12]: COMIRNATY Omicron XBB.1.5 10 micrograms/dose dispersion for injection (EU/1/20/1528/022-023):
1 dose (0.3 mL) contains 10 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--[13]: COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/024):
After dilution, 1 dose (0.2 mL) contains 3 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--[14]: COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/026):
After dilution, 1 dose (0.3 mL) contains 3 micrograms of raxtozinameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Raxtozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron XBB.1.5).

--[15]: COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031, EU/1/20/1528/043):
1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--[16]: COMIRNATY JN.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/032-033):

1 dose (0.3 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--[17]: COMIRNATY JN.1 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/034):
After dilution, 1 dose (0.2 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--[18]: COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/035):
After dilution, 1 dose (0.3 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--[19]: COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/036):
After dilution, 1 dose (0.2 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

--[20]: COMIRNATY KP.2 30 micrograms/dose dispersion for injection (EU/1/20/1528/037-039, EU/1/20/1528/044):
1 dose (0.3 mL) contains 30 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

--[21]: COMIRNATY KP.2 10 micrograms/dose dispersion for injection (EU/1/20/1528/040-041):
1 dose (0.3 mL) contains 10 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

--[22]: COMIRNATY KP.2 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/042):
After dilution, 1 dose (0.3 mL) contains 3 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

--[23]: COMIRNATY LP.8.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/045-047, EU/1/20/1528/051):
1 dose (0.3 mL) contains 30 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).

--[24]: COMIRNATY LP.8.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/048-049):
1 dose (0.3 mL) contains 10 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).

--[25]: COMIRNATY LP.8.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/050):
After dilution, 1 dose (0.3 mL) contains 3 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).
The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).